
SBFLOX-MZ+ Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
SBFLOX-MZ+
Ofloxacin 50mg + Metronidazole 120mg + Simethicone 10mg
SBFLOX-MZ+ is a broad-spectrum bactericidal antimicrobial agent exhibiting enhanced pharmacokinetic tissue penetration against susceptible gram-positive and gram-negative pathogens.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Inhibits bacterial DNA gyrase (type II topoisomerase) and topoisomerase IV enzymes required for bacterial DNA replication, transcription, and repair.
Adult: One dose once or twice daily depending on infectious severity. Complete full course to prevent antimicrobial resistance.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C. Do not freeze. Keep container tightly closed.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
SBFLOX-MZ+ features Ofloxacin 50mg + Metronidazole 120mg + Simethicone 10mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Prescribed in our outpatient depart for SBFLOX-MZ+
SBFLOX-MZ+ has been prescribed in our outpatient department for over eight months, providing dependable relief from acute discomfort without noticeable lethargy. Bottles and blister strips feature secure tamper-resistant seals that chemists and patients appreciate. Patients frequently remark on the rapid symptomatic comfort and ease of taking this formulation.
Questions Regarding SBFLOX-MZ+
What is the therapeutic indication and composition of SBFLOX-MZ+?
SBFLOX-MZ+ contains Ofloxacin 50mg + Metronidazole 120mg + Simethicone 10mg indicated for Lower Respiratory Tract Infections as formulated by Sygnus Biotech.
What packaging presentations are available for SBFLOX-MZ+?
SBFLOX-MZ+ is supplied in tamper-evident 100ml / 200ml PET Bottle with Graduated Measuring Cap, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for SBFLOX-MZ+?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for SBFLOX-MZ+ along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
SBFLOX-MZ+ is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.





